These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 18805705)

  • 1. An improved abnormal toxicity test by using reference vaccine-specific body weight curves and histopathological data for monitoring vaccine quality and safety in Japan.
    Mizukami T; Masumi A; Momose H; Kuramitsu M; Takizawa K; Naito S; Maeyama J; Furuhata K; Tsuruhara M; Hamaguchi I; Yamaguchi K
    Biologicals; 2009 Jan; 37(1):8-17. PubMed ID: 18805705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is the abnormal toxicity test still relevant for the safety of vaccines, sera and immunoglobulins?
    Krämer B; Nagel M; Duchow K; Schwanig M; Cussler K
    ALTEX; 1996; 13(1):7-16. PubMed ID: 11178440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 4R concept for the safety testing of immunobiologicals.
    Cussler K
    Dev Biol Stand; 1999; 101():121-6. PubMed ID: 10566784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in European legislation make it timely to introduce a transparent market surveillance system for cosmetics.
    Lodén M; Ungerth L; Serup J
    Acta Derm Venereol; 2007; 87(6):485-92. PubMed ID: 17989885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. WHO Expert Committee on Biological Standardization.
    World Health Organ Tech Rep Ser; 2002; 904():i-vi, 1-107. PubMed ID: 11980231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assuring the quality and safety of vaccines: regulatory licensing and batch release.
    Griffiths E; Knezevic I
    Methods Mol Med; 2003; 87():353-76. PubMed ID: 12958467
    [No Abstract]   [Full Text] [Related]  

  • 7. A global perspective on vaccine safety.
    Duclos P
    Vaccine; 2004 May; 22(15-16):2059-63. PubMed ID: 15121323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The views and policy of the Japanese control authorities on the three Rs.
    Chino F
    Dev Biol Stand; 1996; 86():53-62. PubMed ID: 8785992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A population-based, postlicensure evaluation of the safety of a combination diphtheria, tetanus, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine in a large managed care organization.
    Zangwill KM; Eriksen E; Lee M; Lee J; Marcy SM; Friedland LR; Weston W; Howe B; Ward JI
    Pediatrics; 2008 Dec; 122(6):e1179-85. PubMed ID: 19047220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safe use of vaccines and vaccine compliance with food safety requirements.
    Grein K; Papadopoulos O; Tollis M
    Rev Sci Tech; 2007 Aug; 26(2):339-50. PubMed ID: 17892156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New challenges in assuring vaccine quality.
    Dellepiane N; Griffiths E; Milstien JB
    Bull World Health Organ; 2000; 78(2):155-62. PubMed ID: 10743279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evaluation of the safety of live attenuated vaccine viruses against infectious bursal disease (Gumboro disease) in conventional broiler chicks].
    Boudaoud A; Alloui N
    Rev Sci Tech; 2008 Dec; 27(3):793-802. PubMed ID: 19284047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Towards eliminating the use of animals for regulatory required vaccine quality control.
    Hendriksen CF
    ALTEX; 2006; 23(3):187-90. PubMed ID: 17086348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ensuring the quality, potency and safety of vaccines during preclinical development.
    Lebron JA; Wolf JJ; Kaplanski CV; Ledwith BJ
    Expert Rev Vaccines; 2005 Dec; 4(6):855-66. PubMed ID: 16372881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Historical data analyses and scientific knowledge suggest complete removal of the abnormal toxicity test as a quality control test.
    Garbe JHO; Ausborn S; Beggs C; Bopst M; Joos A; Kitashova AA; Kovbasenco O; Schiller CD; Schwinger M; Semenova N; Smirnova L; Stodart F; Visalli T; Vromans L
    J Pharm Sci; 2014 Nov; 103(11):3349-3355. PubMed ID: 25209378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulations and procedures in parasite vaccine development.
    Schetters TP; Gravendyck M
    Parasitology; 2006; 133 Suppl():S189-95. PubMed ID: 17274846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current status and future directions of post-marketing vaccine safety monitoring with focus on USA and Europe.
    Bonhoeffer J; Black S; Izurieta H; Zuber P; Sturkenboom M
    Biologicals; 2012 Sep; 40(5):393-7. PubMed ID: 22902972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety experience with heptavalent pneumococcal CRM197-conjugate vaccine (Prevenar) since vaccine introduction.
    Center KJ; Strauss A
    Vaccine; 2009 May; 27(25-26):3281-4. PubMed ID: 19200818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bad medicine. Monitoring programs target substandard drugs.
    Grens K
    Mod Healthc; 2013 May; 43(20):30-1. PubMed ID: 23947275
    [No Abstract]   [Full Text] [Related]  

  • 20. The Intensive Vaccines Monitoring Programme (IVMP): an electronic system to monitor vaccine safety in New Zealand.
    Tatley MV; Kunac DL; McNicholas A; Zhou L; Ballantyne S; Ashton J; Stehr-Green P; Galloway Y; Reid S
    Vaccine; 2008 May; 26(22):2746-52. PubMed ID: 18430496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.